Sunshine Biopharma, Inc.

79 articles with Sunshine Biopharma, Inc.

• Sunshine Biopharma Reports Favorable MTD Results for COVID-19 Treatment

  4/19/2021

  Sunshine Biopharma Inc. (OTC PINK: “SBFM”), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs, today announced that it has successfully completed a Maximum Tolerated Dose (MTD) study in mice.

• Sunshine Biopharma Reaches $2,000,000+ Financing for Coronavirus Treatment

  3/23/2021

  Sunshine Biopharma Inc. (OTC PINK: “SBFM”), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs, today announced that it has received a total of $2,054,000 to date from the recently announced committed minimum financing of $2,000,000 with RB Capital Partners Inc.

• Sunshine Biopharma Receives Notice of Allowance for a New Patent Application Extending Protection of Adva-27a in Europe Until 2033

  3/11/2021

  Sunshine Biopharma Inc. (OTC PINK: “SBFM”), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs today announced that it has received a “Notice of Allowance” from the European Patent Office for a new patent application covering Adva-27a, the Company’s flagship anticancer compound.

• Sunshine Biopharma Receives Recently Ordered New Batch of Adva-27a and Initiates QA/QC Testing

  3/4/2021

  Sunshine Biopharma Inc., a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs, announced that it has received shipment of a new batch of Adva-27a from its manufacturer in China.

• Sunshine Biopharma Initiates COVID-19 Treatment Mice Study

  2/10/2021

  Sunshine Biopharma Inc. (OTC PINK:SBFM), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs, today announced that it has initiated a momentous transgenic mice study of its COVID-19 treatment that has been under development since May of last year.

• Sunshine Biopharma Signs Exclusive License Agreement With University of Georgia for COVID-19 Compounds

  2/4/2021

  Sunshine Biopharma Inc. (OTC PINK:SBFM), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs today announced that it has signed an exclusive license agreement with the University of Georgia for two Anti-Coronavirus compounds which UGA had previously developed and patented. Sunshine Biopharma and UGA will advance the development of these two compounds

• Sunshine Biopharma Receives Notice of Allowance for a New Patent Application Extending Protection of Adva-27a in Canada Until 2033

  2/2/2021

  Sunshine Biopharma Inc. (OTC PINK:SBFM), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs today announced that it has received a ;Notice of Allowance from the Canadian Intellectual Property Office for a new patent application covering Adva-27a, the Companys flagship anticancer compound.

• Sunshine Biopharma Completes Application to Uplist to OTCQB

  1/27/2021

  Sunshine Biopharma Inc. (OTC PINK:SBFM), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs, today announced that it has successfully completed and submitted the application to uplist to the OTCQB.

• Sunshine Biopharma Receives Fourth Tranche From Previously Announced $2,000,000 + Financing for Coronavirus Treatment

  1/14/2021

  Sunshine Biopharma Inc., a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs, announced that it has received the fourth tranche of funding under the recently announced committed minimum financing of $2,000,000 with RB Capital Partners Inc.

• Sunshine Biopharma’s Coronavirus Treatment Anticipated to Be Effective Against the New Variant Identified in the UK

  12/22/2020

  Sunshine Biopharma Inc. (OTC PINK:SBFM), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs today announced that its Anti-Coronavirus drug development program is unaffected by the recent discovery of a new strain of Coronavirus in Southern England.

• Sunshine Biopharma Pays Off Convertible Notes in Cash Preventing New Shares From Hitting the Market

  12/3/2020

  Sunshine Biopharma Inc. (OTC PINK:SBFM), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs, today announced that it has paid off just over $100,000 worth of convertible notes associated with the Company.

• Sunshine Biopharma Receives Third Tranche From Previously Announced $2,000,000 + Financing for Coronavirus Treatment

  12/1/2020

  Sunshine Biopharma Inc. (OTC PINK:SBFM), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs, today announced that it has received the third tranche of funding under the recently announced committed minimum financing of $2,000,000 with RB Capital Partners Inc.

• Sunshine Biopharma Believes That an Effective Coronavirus Treatment Continues to Be Necessary

  11/24/2020

  Sunshine Biopharma Inc., a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs announced that it is pushing ahead with its Anti-Coronavirus drug development program.

• Sunshine Biopharma Signs an Agreement with a Montreal-based Company to Advance the Development of Adva-27a Anticancer Compound

  11/18/2020

  Sunshine Biopharma Inc. (OTC PINK:SBFM), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs today announced that it has entered into a collaboration agreement with Montreal-based company for the purposes of advancing the development of Sunshine Biopharmas anticancer compound, Adva-27a.

• Sunshine Biopharma Signs an Agreement for Distribution of Essential-9(TM) in Asia and the Far East

  11/10/2020

  Sunshine Biopharma, Inc. oday announced that it has signed an agreement with JOAH International Pte., Ltd., headquartered in Singapore for distribution of Essential-9tm in Asia and the Far East.

• Sunshine Biopharma Receives Second Tranche From Previously Announced $2,000,000 + Financing for Coronavirus Treatment

  10/26/2020

  Sunshine Biopharma Inc., a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs, announced that it has received the second tranche of funding under the recently announced committed minimum financing of $2,000,000 with RB Capital Partners Inc.

• Sunshine Biopharma Secures $2,000,000 + Financing for Coronavirus Treatment

  9/15/2020

  Sunshine Biopharma Inc. today announced that it has received the first tranche of $250,000 as part of a committed minimum financing of $2 Million with RB Capital Partners Inc.

• Sunshine Biopharma Completes the Synthesis of Four Potential Inhibitors of Coronavirus Protease

  8/25/2020

  Sunshine Biopharma Inc. (OTC PINK:SBFM), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs today announced that it has completed the synthesis of four different potential inhibitors of Coronavirus protease.

• Sunshine Biopharma, Inc. Signs Licensing Agreement For Three Additional Generic Products For Treatment Of Cancer And BPH

  6/30/2016

• Sunshine Biopharma, Inc. Signs Licensing Agreement For Anastrozole, The Company's First Generic Drug For Treatment Of Breast Cancer

  5/12/2016